Dec 30 (Reuters) - Johnson & Johnson JNJ.N:
J&J: EC APPROVES RYBREVANT IN COMBINATION WITH LAZCLUZE FOR FIRST-LINE TREATMENT OF PATIENTS WITH EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))